Today: 21 December 2025
Subscribe
Browse Category

NYSE:PFE News 4 November 2025 - 12 November 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Nasdaq Rally Hits Speed Bump as Tech Stocks Wobble – Fed Warning and AI Jitters Shake Markets (Sept 24–25, 2025)

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Published: November 10, 2025 Key takeaways Market snapshot: AI leads early rebound U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board
10 November 2025
 ·  ·  ·  ·  ·  · 
Tariff Shock and Fed Jitters: Asian Markets Stumble as Rally Meets Reality

What to Know Before the U.S. Stock Market Opens Today (Nov. 10, 2025): Futures Jump on Shutdown-Deal Hopes; Tyson, Occidental and AI Mega-Caps in Focus

TL;DR Futures and Global Backdrop U.S. equities are set to open higher Monday as traders react to signs of progress in Washington. Pre‑market, S&P 500 and Nasdaq‑100 futures rose while Dow futures edged up, tracking a global relief rally after
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity
8 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Last updated: Nov 7, 2025 (19:23 UTC) Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print,
7 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways What happened today (Nov. 6) 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger
6 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence
5 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com,
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of
4 November 2025
 ·  ·  ·  ·  ·  · 
1 … 3 4 5 6 7 8
Go toTop